Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

BiomeDxRx

Financiado

Microbiome-based diagnostics and therapeutics

The problem: Much effort has been directed to identifying disease risk factors and indeed, numerous genetic, lifestyle, anthropometric and clinical risk factors are routinely used for this task. However, the clinical utility of ex... ver más

31/03/2025

WEIZMANN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-06-05

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

WEIZMANN

150.00K€ | Lider

Proyectos interesantes

CGL2015-71523-REDC GENOMICA COMPARADA MICROBIANA 52K€ Cerrado

SAF2009-13032-C02-01 METAGENOMICA POBLACIONAL DE COMUNIDADES MICROBIANAS HUMANAS 392K€ Cerrado

SAF2012-38421 METAGENOMICA DE VIRUS EN PATOLOGIAS FRECUENTES DE LA CAVIDAD... 94K€ Cerrado

CSIC10-1E-226 Pirosecuenciador para ultrasecuenciación Escala Media 157K€ Cerrado

PID2021-125158OA-I00 INTEGRACION MULTI-OMICA APLICADA A CASOS DE ENFERMEDADES RAR... 152K€ Cerrado

Perseus MAP Microbiome Abundance Profiling: Precision microbiome profili... 4M€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 21 meses Fecha Inicio: 2023-06-05
Fecha Fin: 2025-03-31

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto The problem: Much effort has been directed to identifying disease risk factors and indeed, numerous genetic, lifestyle, anthropometric and clinical risk factors are routinely used for this task. However, the clinical utility of existing risk factors is limited and most of them appear when physiological derangements have already occurred. The gut microbiome plays a role in human physiology and health and as such, combining it with existing risk factors can lead to earlier and more robust disease detection. However, very few microbiome-based markers predictive of disease onset and progression were found to date and none are currently used by healthcare systems. The solution: In the ERC-funded project, we used our unique multi-omics and longitudinally profiled 10,000-person cohort and biobank to develop methods for metagenome-wide association studies. We found microbial genetic variation at the single nucleotide level and single bacterial genes level whose baseline levels were predictive of future disease onset. In this ERC-PoC, we propose to prioritize the bacteria found in the ERC-funded project (WP1) and use them within machine learning disease diagnostic models (WP2) that we will then license to diagnostic companies. We further propose to build a microbial biobank of the ERC-identified strains by isolating them from cohort participants, functionally characterizing them with metabolomics and combining them into bacterial consortiums (WP3). As these strains have therapeutic potential, we will license them to probiotic or pharmaceutical companies (WP4). Notably, we already validated this approach in two licensing agreements, one with a Japanese-based company who licensed bacteria that we found for treating Atopic Dermatitis, and another with a U.S. based probiotics company who licensed bacteria that we found for weight loss. If successful, our ERC-PoC may thus result in novel microbiome-based diagnostic and therapeutic products for various disease indications.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores